GUERBET (GBT.PA) Stock Fundamental Analysis
EPA:GBT - Euronext Paris - Matif - FR0000032526 - Common Stock - Currency: EUR
We assign a fundamental rating of 4 out of 10 to GBT. GBT was compared to 54 industry peers in the Health Care Equipment & Supplies industry. GBT has only an average score on both its financial health and profitability. GBT is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year GBT was profitable.
In the past year GBT had a positive cash flow from operations.
Of the past 5 years GBT 4 years were profitable.
GBT had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of GBT (1.55%) is comparable to the rest of the industry.
GBT has a Return On Equity (4.08%) which is comparable to the rest of the industry.
The Return On Invested Capital of GBT (4.48%) is comparable to the rest of the industry.
GBT had an Average Return On Invested Capital over the past 3 years of 4.08%. This is below the industry average of 7.93%.
The last Return On Invested Capital (4.48%) for GBT is above the 3 year average (4.08%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.55% | ||
| ROE | 4.08% | ||
| ROIC | 4.48% |
ROA(3y)-0.17%
ROA(5y)0.94%
ROE(3y)-0.15%
ROE(5y)2.51%
ROIC(3y)4.08%
ROIC(5y)3.99%
1.3 Margins
The Profit Margin of GBT (1.91%) is comparable to the rest of the industry.
In the last couple of years the Profit Margin of GBT has declined.
GBT's Operating Margin of 5.89% is in line compared to the rest of the industry. GBT outperforms 53.70% of its industry peers.
In the last couple of years the Operating Margin of GBT has declined.
With an excellent Gross Margin value of 77.94%, GBT belongs to the best of the industry, outperforming 81.48% of the companies in the same industry.
In the last couple of years the Gross Margin of GBT has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.89% | ||
| PM (TTM) | 1.91% | ||
| GM | 77.94% |
OM growth 3Y2.51%
OM growth 5Y-2.16%
PM growth 3Y-24.58%
PM growth 5Y-15.99%
GM growth 3Y1.72%
GM growth 5Y0.58%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so GBT is destroying value.
The number of shares outstanding for GBT remains at a similar level compared to 1 year ago.
The number of shares outstanding for GBT has been increased compared to 5 years ago.
The debt/assets ratio for GBT is higher compared to a year ago.
2.2 Solvency
GBT has an Altman-Z score of 2.16. This is not the best score and indicates that GBT is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of GBT (2.16) is comparable to the rest of the industry.
GBT has a debt to FCF ratio of 16.18. This is a negative value and a sign of low solvency as GBT would need 16.18 years to pay back of all of its debts.
The Debt to FCF ratio of GBT (16.18) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.89 indicates that GBT is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.89, GBT is not doing good in the industry: 72.22% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.89 | ||
| Debt/FCF | 16.18 | ||
| Altman-Z | 2.16 |
ROIC/WACC0.69
WACC6.52%
2.3 Liquidity
GBT has a Current Ratio of 2.32. This indicates that GBT is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of GBT (2.32) is better than 70.37% of its industry peers.
A Quick Ratio of 1.13 indicates that GBT should not have too much problems paying its short term obligations.
The Quick ratio of GBT (1.13) is better than 61.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.32 | ||
| Quick Ratio | 1.13 |
3. Growth
3.1 Past
The earnings per share for GBT have decreased strongly by -34.20% in the last year.
GBT shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -15.50% yearly.
Looking at the last year, GBT shows a small growth in Revenue. The Revenue has grown by 7.05% in the last year.
GBT shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.59% yearly.
EPS 1Y (TTM)-34.2%
EPS 3Y-21.06%
EPS 5Y-15.5%
EPS Q2Q%-77.4%
Revenue 1Y (TTM)7.05%
Revenue growth 3Y4.74%
Revenue growth 5Y0.59%
Sales Q2Q%3.65%
3.2 Future
Based on estimates for the next years, GBT will show a small growth in Earnings Per Share. The EPS will grow by 7.05% on average per year.
Based on estimates for the next years, GBT will show a small growth in Revenue. The Revenue will grow by 4.21% on average per year.
EPS Next Y-1.67%
EPS Next 2Y8.02%
EPS Next 3Y7.05%
EPS Next 5YN/A
Revenue Next Year4.7%
Revenue Next 2Y4.9%
Revenue Next 3Y4.21%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 15.43, GBT is valued correctly.
87.04% of the companies in the same industry are more expensive than GBT, based on the Price/Earnings ratio.
GBT is valuated rather cheaply when we compare the Price/Earnings ratio to 28.98, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 7.75, the valuation of GBT can be described as very cheap.
GBT's Price/Forward Earnings ratio is rather cheap when compared to the industry. GBT is cheaper than 92.59% of the companies in the same industry.
GBT is valuated cheaply when we compare the Price/Forward Earnings ratio to 21.38, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.43 | ||
| Fwd PE | 7.75 |
4.2 Price Multiples
94.44% of the companies in the same industry are more expensive than GBT, based on the Enterprise Value to EBITDA ratio.
94.44% of the companies in the same industry are more expensive than GBT, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.23 | ||
| EV/EBITDA | 3.94 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.02%
EPS Next 3Y7.05%
5. Dividend
5.1 Amount
No dividends for GBT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:GBT (4/29/2025, 7:00:00 PM)
19.6
-0.16 (-0.81%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners18.97%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap247.74M
Analysts85
Price Target33.92 (73.06%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.5
Dividend Growth(5Y)-10.05%
DP39.2%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-20.36%
PT rev (3m)-21.76%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-23.16%
EPS NY rev (3m)-23.04%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.86%
Revenue NY rev (3m)-4.09%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.43 | ||
| Fwd PE | 7.75 | ||
| P/S | 0.29 | ||
| P/FCF | 10.23 | ||
| P/OCF | 3.05 | ||
| P/B | 0.63 | ||
| P/tB | 0.86 | ||
| EV/EBITDA | 3.94 |
EPS(TTM)1.27
EY6.48%
EPS(NY)2.53
Fwd EY12.91%
FCF(TTM)1.92
FCFY9.78%
OCF(TTM)6.43
OCFY32.78%
SpS66.54
BVpS31.19
TBVpS22.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.55% | ||
| ROE | 4.08% | ||
| ROCE | 6.33% | ||
| ROIC | 4.48% | ||
| ROICexc | 5.17% | ||
| ROICexgc | 6.14% | ||
| OM | 5.89% | ||
| PM (TTM) | 1.91% | ||
| GM | 77.94% | ||
| FCFM | 2.88% |
ROA(3y)-0.17%
ROA(5y)0.94%
ROE(3y)-0.15%
ROE(5y)2.51%
ROIC(3y)4.08%
ROIC(5y)3.99%
ROICexc(3y)4.66%
ROICexc(5y)4.72%
ROICexgc(3y)5.5%
ROICexgc(5y)6.1%
ROCE(3y)5.76%
ROCE(5y)5.64%
ROICexcg growth 3Y-4.7%
ROICexcg growth 5Y-5.56%
ROICexc growth 3Y2.24%
ROICexc growth 5Y-2.35%
OM growth 3Y2.51%
OM growth 5Y-2.16%
PM growth 3Y-24.58%
PM growth 5Y-15.99%
GM growth 3Y1.72%
GM growth 5Y0.58%
F-Score5
Asset Turnover0.81
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.89 | ||
| Debt/FCF | 16.18 | ||
| Debt/EBITDA | 2.86 | ||
| Cap/Depr | 77.91% | ||
| Cap/Sales | 6.78% | ||
| Interest Coverage | 2.42 | ||
| Cash Conversion | 66.19% | ||
| Profit Quality | 150.63% | ||
| Current Ratio | 2.32 | ||
| Quick Ratio | 1.13 | ||
| Altman-Z | 2.16 |
F-Score5
WACC6.52%
ROIC/WACC0.69
Cap/Depr(3y)72.12%
Cap/Depr(5y)80.72%
Cap/Sales(3y)6.9%
Cap/Sales(5y)7.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-34.2%
EPS 3Y-21.06%
EPS 5Y-15.5%
EPS Q2Q%-77.4%
EPS Next Y-1.67%
EPS Next 2Y8.02%
EPS Next 3Y7.05%
EPS Next 5YN/A
Revenue 1Y (TTM)7.05%
Revenue growth 3Y4.74%
Revenue growth 5Y0.59%
Sales Q2Q%3.65%
Revenue Next Year4.7%
Revenue Next 2Y4.9%
Revenue Next 3Y4.21%
Revenue Next 5YN/A
EBIT growth 1Y28.18%
EBIT growth 3Y7.37%
EBIT growth 5Y-1.59%
EBIT Next Year118.05%
EBIT Next 3Y35.35%
EBIT Next 5YN/A
FCF growth 1Y182.76%
FCF growth 3Y-28.77%
FCF growth 5Y-19.52%
OCF growth 1Y196.03%
OCF growth 3Y-11.2%
OCF growth 5Y-9.16%